Provided by Tiger Fintech (Singapore) Pte. Ltd.

Urogen Pharma Ltd.

15.27
-0.1400-0.91%
Post-market: 15.01-0.2600-1.70%19:24 EDT
Volume:1.20M
Turnover:18.32M
Market Cap:704.06M
PE:-5.02
High:15.80
Open:15.55
Low:14.89
Close:15.41
Loading ...

UroGen Pharma call volume above normal and directionally bullish

TIPRANKS
·
20 hours ago

H.C. Wainwright Reaffirms Their Buy Rating on Urogen Pharma (URGN)

TIPRANKS
·
14 Jul

Optimistic Investors Push UroGen Pharma Ltd. (NASDAQ:URGN) Shares Up 84% But Growth Is Lacking

Simply Wall St.
·
08 Jul

UroGen Pharma Is Maintained at Buy by D. Boral Capital

Dow Jones
·
07 Jul

UroGen Pharma completes enrollment in Phase 3 UTOPIA trial of UGN-103

TIPRANKS
·
07 Jul

UroGen Pharma Ltd. Completes Enrollment in Phase 3 UTOPIA Trial for UGN-103, Aiming to Enhance Treatment of Recurrent Low-Grade Intermediate-Risk Bladder Cancer

Reuters
·
07 Jul

UroGen Pharma Ltd. Awards Special Bonuses to Top Executives Following FDA Approval of ZUSDURI

Reuters
·
04 Jul

HC Wainwright Upgrades UroGen Pharma to Buy From Neutral, $50 Price Target

MT Newswires Live
·
16 Jun

Urogen Pharma Ltd : H.c. Wainwright Raises to Buy From Neutral

THOMSON REUTERS
·
16 Jun

UroGen’s Zusduri approval validates FDA’s flexibility, says D. Boral

TIPRANKS
·
13 Jun

Scotiabank Raises UroGen Pharma Price Target to $47 From $23, Maintains Sector Outperform Rating

MT Newswires Live
·
13 Jun

UroGen Pharma Is Maintained at Buy by D. Boral Capital

Dow Jones
·
13 Jun

Urogen Pharma Says Zusduri Expected To Be Available In U.S. By July 1

Reuters
·
13 Jun

UroGen Pharma Ltd. Secures FDA Approval for ZUSDURI, Revolutionizing Treatment for Recurrent LG-IR-NMIBC

Reuters
·
13 Jun

Urogen Pharma's Bladder Cancer Drug Receives US FDA Approval

MT Newswires Live
·
13 Jun

Urogen Pharma Shares Halted, Pending Material News Release

MT Newswires Live
·
13 Jun

UroGen Pharma trading halted, news pending

TIPRANKS
·
13 Jun

UroGen Pharma put volume heavy and directionally bearish

TIPRANKS
·
11 Jun

Urogen Pharma's Chief Medical Officer Mark Schoenberg Reports Disposal of Common Shares

Reuters
·
11 Jun

Scotiabank Sticks to Its Buy Rating for Urogen Pharma (URGN)

TIPRANKS
·
09 Jun